| Literature DB >> 26624898 |
Qingyu Meng1,2,3, Lvzhen Huang1,2,3, Yaoyao Sun1,2,3, Yujing Bai1,2,3, Bin Wang1,2,3, Wenzhen Yu1,2,3, Mingwei Zhao1,2,3, Xiaoxin Li1,2,3.
Abstract
PURPOSE: To investigate the effect of genetic variants in the high-density lipoprotein (HDL) metabolic pathway and risk factors on neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV) in China.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26624898 PMCID: PMC4666634 DOI: 10.1371/journal.pone.0143924
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Demographic Distribution of the study subjects.
| Controls (n = 221) | nAMD(n = 230) | PCV(n = 291) | |
|---|---|---|---|
| Females, n (%) | 115(52.0) | 84(36.5) | 116(39.9) |
| Age | 45–96 | 50–90 | 42–87 |
| Mean age ± SD | 67.2±9.6 | 69.3±8.8 | 66.6±9.6 |
* Age of presentation.
** SD, standard deviation
nAMD: neovascular age-related macular degeneration; PCV: polypoidal choroidal vasculopathy.
Association between individual SNP and risk factors with nAMD and PCV risk.
| Control | PCV | nAMD | PCV vs Control | nAMD vs Control | ||||
|---|---|---|---|---|---|---|---|---|
| SNP | Risk Allele | A1/A2 | A1/A2 | A1/A2 | OR (95%CI) | P-value | OR (95%CI) | P-value |
|
| G | 44/398 | 53/529 | 40/420 | 0.906 (0.595,1.38) | 0.646 | 0.8615 (0.5495,1.351) | 0.515 |
|
| T | 79/363 | 96/546 | 66/394 | 0.908(0.654,1.259) | 0.562 | 0.7697 (0.5388,1.1) | 0.150 |
|
| A | 209/233 | 228/354 | 192/268 | 1.393(1.084,1.789) |
| 0.7987 (0.6139,1.039) | 0.0938 |
|
| T | 26/416 | 35/547 | 40/240 | 1.024(0.607,1.728) | 0.930 | 1.524 (0.9132,2.543) | 0.105 |
|
| T | 71/371 | 126/456 | 86/374 | 1.444(1.047,1.991) |
| 1.202(0.8505,1.697) | 0.297 |
| Female | 115 | 116 | 84 | 0.611(0.429, 0.870) |
| 0.530(0.364, 0.773) |
| |
| Hypertension | 143 | 183 | 134 | 0.924(0.642, 1.330) | 0.672 | 0.761(0.520, 1.114) | 0.160 | |
| Diabetes Mellitus | 189 | 258 | 186 | 1.324(0.786, 2.229) | 0.292 | 0.716(0.435, 1.178) | 0.188 | |
| Hyperlipidemia | 169 | 264 | 173 | 3.009(1.819, 4.997) |
| 0.934(0.607, 1.438) | 0.756 | |
| CAD | 204 | 284 | 197 | 3.381(1.377,8.302) |
| 0.497(0.268, 0.922) |
| |
nAMD: neovascular age-related macular degeneration; PCV: polypoidal choroidal vasculopathy; CAD: coronary artery disease. SNP: single nucleotide polymorphism.
Association between the cumulative effects of the SNPs and nAMD and PCV risk.
| No. of risk alleles | Control | PCV | nAMD | ORa(95%CI) | Pa | ORb(95%CI) | Pb |
|---|---|---|---|---|---|---|---|
| < = 1 | 37 | 23 | 18 | Ref | Ref | ||
| 2 | 105 | 55 | 51 | 0.843(0.456, 1.557) | 0.585 | 0.998(0.519, 1.922) | 0.996 |
| 3 | 147 | 104 | 100 | 1.138(0.639, 2.028) | 0.661 | 1.398(0.754, 2.594) | 0.288 |
| 4 | 142 | 114 | 102 | 1.291(0.726, 2.297) | 0.384 | 1.477(0.796, 2.739) | 0.217 |
| 5 | 60 | 50 | 54 | 1.341(0.706, 2.547) | 0.371 | 1.850(0.944, 3.625) | 0.073 |
| 6 | 14 | 10 | 7 | 1.149(0.438, 3.013) | 0.778 | 1.028(0.353, 2.990) | 0.960 |
| > = 7 | 9 | 15 | 14 | 2.681(1.010, 7.120) | 0.048 | 3.198(1.166, 8.772) | 0.024 |
ORa, odds ratio of PCV to control
ORb, odds ratio of AMD to control
nAMD: neovascular age-related macular degeneration; PCV: polypoidal choroidal vasculopathy.
Summary of Multifactor Dimensionality Reduction (MDR) results for interactions analysis on nAMD and PCV risk.
| Factors | MDR models | Testing accuracy | CVC |
| OR | footnote |
|---|---|---|---|---|---|---|
|
| ||||||
| 1 | Gender | 0.5771 | 100/100 | 0.0009 | 1.8594 (1.1057,3.1270) |
|
| 2 | rs1532085, gender | 0.5757 | 97/100 | 0.0018 | 2.1212 (1.2558,3.5832) |
|
| 3 | rs12678919, rs1532085, gender | 0.6074 | 100/100 | 0.0000 | 2.5561 (1.5034,4.3459) |
|
| 4 | rs12678919, rs173539, rs1532085, gender | 0.5689 | 81/100 | 0.0060 | 2.9637 (1.7416,5.0435) |
|
| 5 | rs12678919, rs3764261, rs1532085, gender, hypertension | 0.5611 | 98/100 | 0.0018 | 3.9261 (2.2747,6.7765) |
|
|
| ||||||
| 1 | Hyperlipidemia | 0.5580 | 98/100 | 0.0284 | 2.9376 (1.4407,5.9896) |
|
| 2 | rs1532085, hyperlipidemia | 0.5395 | 69/100 | 0.2421 | 2.9052 (1.6133,5.2317) |
|
| 3 | rs10468017, rs1532085, hyperlipidemia | 0.5508 | 91/100 | 0.0666 | 2.6466 (1.6024,4.3712) |
|
| 4 | rs10468017, rs1532085, gender, hyperlipidemia | 0.6325 | 100/100 | 0.0000 | 3.6203 (2.1397,6.1254) |
|
| 5 | rs10468017, rs3764261, rs1532085, gender, hyperlipidemia | 0.6195 | 100/100 | 0.0000 | 4.4125 (2.6154,7.4443) |
|
CVC—Cross-validation consistency
P-value based on 10 000 permutations
Best model with highest CVC and accuracy in bold.
nAMD: neovascular age-related macular degeneration; PCV: polypoidal choroidal vasculopathy.